STOCK TITAN

Akebia Therapeutics (AKBA) Financials

AKBA NASDAQ
Trailing 12 months to September 30, 2026
Revenue $197.2M -12.4% YoY
Net Income -$44.6M n/m YoY
EPS (Diluted) -$0.16 n/m YoY
Free Cash Flow $13.9M -56.9% YoY
Market Cap $117.3M as of Nov 19, 2026
Price / Sales 0.6x on $197.2M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 5.8x on $20.4M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AKBA SEC filings page.

Akebia Therapeutics, Inc. (AKBA) reported $197.2M in revenue over the twelve months to Sep 30, 2026, down 12.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AKBA FY2025

FY2025 marks a shift from cash-consuming development toward positive operating cash flow, though interest expense still keeps net income negative.

The margin step-up reflects a changed revenue-cost mix: revenue rose 47.5% while gross profit increased 102.8%. Meanwhile, SG&A rose only 0.9% as operating income reached $23.5M, pointing to fixed-cost absorption rather than merely a revenue rebound.

Cash conversion improved sharply: operating cash flow reached $68.0M while free cash flow was $67.7M, despite a reported net loss of $5.3M. Capital expenditures were just $291K, so the cash result reflects current operations more than heavy asset spending.

The balance sheet also changed direction, moving from negative equity of $49.2M in FY2024 to positive equity of $32.6M in FY2025. Even after that reversal, liabilities were 91.3% of assets and debt-to-equity was 1.5x, leaving financing material to the business structure.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 49 / 100
Financial Health Score 49/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Akebia Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
22

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Akebia Therapeutics, Inc. scores 22/100 on it among other operating companies.

Growth
65

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Akebia Therapeutics, Inc. scores 65/100 on it among other operating companies.

Leverage
98

Akebia Therapeutics, Inc. held more cash than long-term debt at the end of fiscal year 2025, with $184.8M of cash against $48.3M of long-term debt. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Akebia Therapeutics, Inc. scores 98/100 among other operating companies measured the same way.

Liquidity
45

Akebia Therapeutics, Inc. held $1.55 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.55. Liquidity ranks operating companies on that ratio, and Akebia Therapeutics, Inc. scores 45/100 among other operating companies.

Cash Flow
43

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Akebia Therapeutics, Inc. scores 43/100 on it among other operating companies.

Returns
21

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Akebia Therapeutics, Inc. scores 21/100 on it among other operating companies.

Altman Z-Score Distress
-4.94

Akebia Therapeutics, Inc. scores -4.94, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.7B against total assets of $376.6M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
6/9

Akebia Therapeutics, Inc. passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality Mixed
N/A

Akebia Therapeutics, Inc. reported a net loss of $5.3M while generating $68.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk
0.97x

Akebia Therapeutics, Inc. earns $0.97 in operating income for every $1 of interest expense ($23.5M vs $24.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$36.9M
YoY-37.2%
QoQ-24.9%
5Y CAGR-5.4%

Akebia Therapeutics, Inc. generated $36.9M in revenue in Q3 2026. This represents a decrease of 37.2% from the same quarter a year earlier. Against the prior quarter it is down 24.9%.

EBITDA
-$11.4M
YoY-338.3%
QoQn/m

Akebia Therapeutics, Inc.'s EBITDA was -$11.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 338.3% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$14.4M
YoY-2758.1%
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Akebia Therapeutics, Inc. reported a net loss of $14.4M in Q3 2026. This represents a decrease of 2758.1% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.05
YoYn/m
QoQn/m
5Y CAGRn/m

Akebia Therapeutics, Inc. earned -$0.05 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
$1.6M
YoY-94.2%
QoQ-33.5%
5Y CAGRn/m

Akebia Therapeutics, Inc. generated $1.6M in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 94.2% from the same quarter a year earlier. Against the prior quarter it is down 33.5%.

Cash & Debt
$159.3M
YoY-4.3%
QoQ+2.4%
5Y CAGR-5.1%
10Y CAGR+9.2%

Akebia Therapeutics, Inc. held $159.3M in cash against $12.8M in long-term debt as of Q3 2026, with $162.3M of liabilities due within a year.

Shares Outstanding
278M
YoY+4.6%
QoQ+0.2%
5Y CAGR+9.7%

Akebia Therapeutics, Inc. had 278M shares outstanding in Q3 2026. This represents an increase of 4.6% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
82.8%
YoY-1.3pp
QoQ+4.0pp
5Y change+15.5pp

Akebia Therapeutics, Inc.'s gross margin was 82.8% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.0 percentage points.

Operating Margin
-31.1%
YoY-38.6pp
QoQ-18.2pp

Akebia Therapeutics, Inc.'s operating margin was -31.1% in Q3 2026, reflecting core business profitability. This is down 38.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 18.2 percentage points.

Net Margin
-38.9%
YoY-39.8pp
QoQ-20.8pp

Akebia Therapeutics, Inc.'s net profit margin was -38.9% in Q3 2026, showing the share of revenue converted to profit. This is down 39.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.8 percentage points.

Return on Equity
-70.5%
YoY-71.8pp
QoQ-34.9pp

Akebia Therapeutics, Inc.'s quarterly ROE was -70.5% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 71.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 34.9 percentage points.

Capital Allocation

R&D Spending
$16.2M
YoY+8.3%
QoQ+15.1%
5Y CAGR-16.8%

Akebia Therapeutics, Inc. invested $16.2M in research and development in Q3 2026. This represents an increase of 8.3% from the same quarter a year earlier. Against the prior quarter it is up 15.1%.

Capital Expenditures
$706K
YoY+816.9%
QoQ-34.6%
5Y CAGRn/m

Akebia Therapeutics, Inc. invested $706K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 816.9% from the same quarter a year earlier. Against the prior quarter it is down 34.6%.

Share Buybacks

Not reported for Q3 2026.

AKBA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AKBA quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$36.9M-37.2%$49.1M-21.4%$53.5M-6.6%$57.6M+23.9%$58.8M+57.0%$62.5M+43.1%$57.3M+75.8%$46.5M-17.3%
Cost of Revenue$6.4M-32.2%$10.4M+5.1%$12.3M+61.2%$12.5M-38.4%$9.4M-33.7%$9.9M-41.8%$7.6M-34.3%$20.4M+9.1%
Gross Profit$30.5M-38.2%$38.7M-26.4%$41.3M-17.0%$45.1M+72.5%$49.4M+112.2%$52.6M+97.6%$49.7M+136.7%$26.1M-30.4%
R&D Expenses$16.2M+8.3%$14.1M+27.7%$14.8M+51.8%$26.6M+126.1%$14.9M+76.1%$11.0M+44.0%$9.8M+0.2%$11.8M+19.5%
SG&A Expenses$23.5M-19.1%$28.2M+6.1%$30.4M+18.2%$26.1M-5.7%$29.1M+9.7%$26.6M-1.3%$25.7M+1.2%$27.7M+8.8%
Operating Income-$11.5M-357.6%-$6.3M-144.9%-$4.7M-134.7%-$8.6Mn/m$4.4Mn/m$14.1Mn/m$13.5Mn/m-$14.3M-1142.0%
EBITDA-$11.4M-338.3%-$5.7M-139.9%-$4.4M-131.6%-$8.2Mn/m$4.8Mn/m$14.4M+2034.1%$13.8Mn/m-$5.0M-146.0%
Interest Expense$3.1M-33.8%$3.1M-55.1%$4.7M-39.6%$4.8M-29.8%$4.7M-28.7%$6.8M+218.0%$7.8M+211.0%$6.9M+384.6%
Income Tax$175K-71.5%$70Kn/m$126Kn/m$1.0Mn/m$615Kn/m$0$0$0
Net Income-$14.4M-2758.1%-$8.9M-3706.5%-$9.1M-248.1%-$12.2Mn/m$540Kn/m$247Kn/m$6.1Mn/m-$22.8M-3826.1%
EPS (Basic)-$0.05n/m-$0.03n/m-$0.03-200.0%-$0.05n/m$0.00n/m$0.00n/m$0.03n/m-$0.11n/m
EPS (Diluted)-$0.05n/m-$0.03n/m-$0.03-200.0%-$0.05n/m$0.00n/m$0.00n/m$0.03n/m-$0.11n/m
Diluted Shares (Avg)277M+0.9%270M-0.6%267M+10.5%N/A274M+30.4%271M+29.3%242M+17.9%N/A

AKBA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AKBA quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$342.1M-6.0%$349.7M+1.2%$362.5M+16.9%$376.6M+70.6%$364.2M+75.8%$345.6M+56.9%$310.2M+37.6%$220.7M-8.7%
Current Assets$220.8M-14.5%$229.6M-2.2%$243.5M+19.5%$253.0M+122.2%$258.3M+158.0%$234.7M+109.3%$203.8M+80.4%$113.8M-3.7%
Cash & Equivalents$159.3M-4.3%$155.5M+13.3%$162.6M+43.5%$184.8M+256.4%$166.4M+389.3%$137.3M+247.6%$113.4M+170.2%$51.9M+20.8%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Inventory$18.7M+0.3%$13.0M-22.1%$13.0M-34.1%$15.6M-3.9%$18.6M-9.0%$16.7M-30.0%$19.7M-22.7%$16.2M+3.5%
Accounts Receivable$36.4M-45.0%$53.5M-26.5%$62.5M+1.6%$47.0M+36.8%$66.2M+105.9%$72.8M+144.6%$61.5M+131.2%$34.4M-12.5%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$59.0M0.0%$59.0M0.0%$59.0M0.0%$59.0M0.0%$59.0M0.0%$59.0M0.0%$59.0M0.0%$59.0M0.0%
Total Liabilities$321.8M-0.2%$324.6M+2.6%$335.1M+17.3%$344.0M+27.5%$322.6M+25.2%$316.4M+24.6%$285.6M+13.0%$269.9M-0.9%
Current Liabilities$162.3M+21.7%$160.9M+35.5%$173.9M+90.6%$162.9M+101.4%$133.4M+103.0%$118.7M+10.6%$91.2M+37.2%$80.9M-19.0%
Non-Current Liabilities$159.4M-15.7%$163.8M-17.1%$161.3M-17.0%$181.0M-4.2%$189.2M-1.4%$197.7M+34.8%$194.4M+4.4%$188.9M+9.6%
Long-Term Debt$12.8M-73.2%$24.8M-47.4%$36.4M-21.7%$48.3M+24.7%$47.6M+24.2%$47.1M+23.7%$46.5M+54.3%$38.7M+125.2%
Total Equity$20.4M-51.0%$25.0M-14.4%$27.4M+11.4%$32.6Mn/m$41.6Mn/m$29.2Mn/m$24.6Mn/m-$49.2Mn/m
Retained Earnings-$1.7Bn/m-$1.7Bn/m-$1.7Bn/m-$1.7Bn/m-$1.7Bn/m-$1.7Bn/m-$1.7Bn/m-$1.7Bn/m

AKBA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AKBA quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$2.3M-91.7%$3.5M-84.2%-$21.2Mn/m$31.1Mn/m$28.1Mn/m$22.3Mn/m-$13.6Mn/m-$4.5Mn/m
Depreciation & Amortization$101K-68.2%$585K+85.1%$328K+4.5%$321K-96.6%$318K-96.6%$316K-96.6%$314K-96.7%$9.3M-0.6%
Stock-Based Compensation$2.8M-13.0%$3.2M+20.6%$3.7M+67.7%N/A$3.2M+95.7%$2.7M+29.2%$2.2M-7.3%N/A
Capital Expenditures$706K+816.9%$1.1M+756.3%$62K+244.4%$70K+3400.0%$77K+3750.0%$126K+334.5%$18Kn/m$2Kn/m
Free Cash Flow$1.6M-94.2%$2.4M-89.0%-$21.3Mn/m$31.1Mn/m$28.0Mn/m$22.2Mn/m-$13.6Mn/m-$4.5Mn/m
Investing Cash Flow-$2.6Mn/m-$4.1Mn/m-$62K-140.3%-$7.9Mn/m-$77Kn/m-$126Kn/m$154Kn/m-$2Kn/m
Financing Cash Flow$3.2M+185.4%-$6.5M-480.1%-$926K-101.2%-$4.8M-121.7%$1.1M-9.0%$1.7M-77.5%$74.9M+305.6%$22.3Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

AKBA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AKBA quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin82.8%-1.3pp78.8%-5.3pp77.0%-9.7pp78.3%+22.0pp84.0%+21.9pp84.1%+23.2pp86.7%+22.3pp56.2%-10.6pp
Operating Margin-31.1%-38.6pp-12.9%-35.4pp-8.8%-32.3pp-14.8%+15.9pp7.6%+41.0pp22.6%+42.5pp23.6%+69.4pp-30.8%-33.2pp
Net Margin-38.9%-39.8pp-18.1%-18.5pp-16.9%-27.6pp-21.3%+27.8pp0.9%+54.5pp0.4%+20.1pp10.7%+65.8pp-49.0%-50.1pp
Return on Equity-70.5%-71.8pp-35.6%-36.5pp-33.1%-57.9pp-37.5%1.3%0.9%24.9%N/A
Return on Assets-4.2%-4.4pp-2.5%-2.6pp-2.5%-4.5pp-3.3%+7.1pp0.1%+9.8pp0.1%+4.0pp2.0%+9.9pp-10.3%-10.6pp
Current Ratio1.36-0.6x1.43-0.5x1.40-0.8x1.55+0.1x1.94+0.4x1.98+0.9x2.23+0.5x1.41+0.2x
Debt-to-Equity0.63-0.5x0.99-0.6x1.33-0.6x1.481.151.611.89N/A
Liabilities-to-Equity15.80+8.0x12.98+2.2x12.24+0.6x10.557.7610.8311.62N/A
Asset Turnover0.11-0.1x0.140.0x0.150.0x0.15-0.1x0.160.0x0.180.0x0.180.0x0.210.0x
FCF Margin4.4%-43.3pp5.0%-30.6pp-39.7%-16.0pp53.9%+63.5pp47.7%+65.6pp35.6%+58.7pp-23.7%+35.9pp-9.6%-5.5pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Akebia Therapeutics, Inc. AKBA FY2025 $236.2M -$5.3M -2.3% $117.3M 49/100
Cardiol Therapeutics Inc. CRDL FY2025 N/A -$24.7M N/A $112.7M —
Journey Medical Corporation DERM FY2025 $61.9M -$11.4M -18.5% $100.2M 31/100
Anika Therapeutics Inc ANIK FY2025 $112.8M -$10.9M -9.6% $177.9M 74/100
Organigram Global Inc. OGI FY2025 $186.1M -$17.8M -9.6% $88.8M 53/100
Organogenesis Holdings Inc. ORGO FY2025 $564.2M $37.0M 6.6% $102.4M 51/100

Frequently Asked Questions

Akebia Therapeutics, Inc. (AKBA) reported $236.2M in total revenue for fiscal year 2025. This represents a 47.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Akebia Therapeutics, Inc. (AKBA) revenue grew by 47.5% year-over-year, from $160.2M to $236.2M in fiscal year 2025.

No, Akebia Therapeutics, Inc. (AKBA) reported a net loss of $44.6M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $5.3M, with a net profit margin of -2.3%.

Akebia Therapeutics, Inc. (AKBA) reported diluted earnings per share of -$0.02 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Akebia Therapeutics, Inc. (AKBA) had EBITDA of $24.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Akebia Therapeutics, Inc. (AKBA) had $184.8M in cash and equivalents against $48.3M in long-term debt.

Akebia Therapeutics, Inc. (AKBA) had a gross margin of 83.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Akebia Therapeutics, Inc. (AKBA) had an operating margin of 10.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Akebia Therapeutics, Inc. (AKBA) had a net profit margin of -2.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Akebia Therapeutics, Inc. (AKBA) has a return on equity of -16.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Akebia Therapeutics, Inc. (AKBA) generated $67.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Akebia Therapeutics, Inc. (AKBA) generated $68.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Akebia Therapeutics, Inc. (AKBA) had $376.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Akebia Therapeutics, Inc. (AKBA) invested $291K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Akebia Therapeutics, Inc. (AKBA) invested $62.4M in research and development during fiscal year 2025.

Akebia Therapeutics, Inc. (AKBA) had 268M shares outstanding as of fiscal year 2025.

Akebia Therapeutics, Inc. (AKBA) had a current ratio of 1.55 as of fiscal year 2025, which is generally considered healthy.

Akebia Therapeutics, Inc. (AKBA) had a debt-to-equity ratio of 1.48 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Akebia Therapeutics, Inc. (AKBA) had a liabilities-to-equity ratio of 10.55 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Akebia Therapeutics, Inc. (AKBA) had a return on assets of -1.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Akebia Therapeutics, Inc. (AKBA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $117.3M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Akebia Therapeutics, Inc. (AKBA) trades at 0.6x sales, its market capitalization divided by $197.2M revenue, trailing 12 months to September 30, 2026. The market capitalization is $117.3M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Akebia Therapeutics, Inc. (AKBA) has an Altman Z-Score of -4.94, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Akebia Therapeutics, Inc. (AKBA) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Akebia Therapeutics, Inc. (AKBA) reported a net loss of $5.3M while generating $68.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Akebia Therapeutics, Inc. (AKBA) has an interest coverage ratio of 0.97x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Akebia Therapeutics, Inc. (AKBA) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top